Roche (RHHBY.US) will finalize its $1.5 billion acquisition of Poseida (PSTX.US), a US-based biopharmaceutical company.

Roche (RHHBY.US) announced on Wednesday that it plans to complete its acquisition of Poseida Therapeutics (PSTX.US), a US biopharmaceutical company focused on developing complex immunotherapies for various types of cancer.

Roche said it has accepted to pay Poseida nearly 65 million shares, or 66% of the company's stock, for a price of $9 per share, and additional potential payments of up to $4 per share.

With this in mind, the deal is worth up to about $1.5 billion.

The acquisition, which was announced in November last year, is the latest move by Roche to expand its pipeline to offset declining sales of its cancer drugs.

Roche said on Wednesday: "Later today, Roche intends to complete the acquisition of Poseida... without a vote or a Poseida shareholder meeting."

Under the acquisition, all Poseida shares not owned by Roche or Poseida will be converted into the right to receive the same price per share.

Poseida will become a wholly owned subsidiary of Roche, adding so-called allogeneic CAR-T cell therapies that use genetically engineered immune cells to attack cancer cells or treat autoimmune diseases.

Poseida is also working on CAR-T projects for solid tumors and autoimmune diseases.